Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Escitalopram Oxalate

FDA-approved product (tablet, oral), marketed as Escitalopram, Escitalopram Oxalate, Lexapro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Escitalopram Oxalate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Depressive disorder
  • Generalized anxiety disorder
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Escitalopram Oxalate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Escitalopram Oxalate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Influence of Escitalopram on Fear Conditioning

    NCT01398514 · start 2008-10

    Registered record
    Registry ID
    NCT01398514
    Conditions
    Fear Conditioning
    Interventions
    Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-10
    Completion
    2011-06
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFear Conditioning
    InterventionEscitalopram
    PhasePhase 4
    Registry statusCompleted

  • Dementia Antipsychotics And Antidepressants Discontinuation Study

    NCT00594269 · start 2008-08

    Registered record
    Registry ID
    NCT00594269
    Conditions
    Dementia
    Interventions
    Risperidone; Escitalopram; Citalopram; Sertraline; Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-08
    Completion
    2010-12
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia
    InterventionRisperidone; Escitalopram; Citalopram; Sertraline +1 more
    PhasePhase 4
    Registry statusCompleted

  • Cipralex® for Anxiety Disorders in Adolescents

    NCT01293838 · start 2008-03

    Registered record
    Registry ID
    NCT01293838
    Conditions
    Anxiety Disorder
    Interventions
    Cipralex®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2008-03
    Completion
    2012-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorder
    InterventionCipralex®
    PhasePhase 1
    Registry statusUnknown

  • Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy

    NCT00598052 · start 2007-12

    Registered record
    Registry ID
    NCT00598052
    Conditions
    Marijuana Dependence
    Interventions
    Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2007-12
    Completion
    2008-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMarijuana Dependence
    InterventionEscitalopram
    PhaseNot applicable
    Registry statusUnknown

  • Functional Neuroimaging in Depression

    NCT00343070 · start 2007-03

    Registered record
    Registry ID
    NCT00343070
    Conditions
    Major Depression
    Interventions
    Oral administration of escitalopram during 8 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2009-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression
    InterventionOral administration of escitalopram during 8 weeks
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

    NCT00432614 · start 2007-01

    Registered record
    Registry ID
    NCT00432614
    Conditions
    Major Depressive Disorder
    Interventions
    SR58611A; escitalopram; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-02
    Enrolment
    510

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionSR58611A; escitalopram; placebo
    PhasePhase 3
    Registry statusCompleted

  • Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment

    NCT03927950 · start 2007-01

    Registered record
    Registry ID
    NCT03927950
    Conditions
    Major Depression
    Interventions
    escitalopram; bupropion
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-01
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression
    Interventionescitalopram; bupropion
    PhasePhase 4
    Registry statusCompleted

  • Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism

    NCT00397059 · start 2006-12

    Registered record
    Registry ID
    NCT00397059
    Conditions
    Healthy
    Interventions
    Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-12
    Completion
    2007-10
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEscitalopram
    PhasePhase 4
    Registry statusCompleted

  • SSRI and Buprenorphine

    NCT00475878 · start 2006-12

    Registered record
    Registry ID
    NCT00475878
    Conditions
    Opiate Dependence; Depression
    Interventions
    escitalopram; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-12
    Completion
    2009-09
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpiate Dependence; Depression
    Interventionescitalopram; placebo
    PhasePhase 3
    Registry statusCompleted

  • An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder

    NCT00358631 · start 2006-07

    Registered record
    Registry ID
    NCT00358631
    Conditions
    Depressive Disorder
    Interventions
    SSR149415
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-07
    Completion
    2007-12
    Enrolment
    319

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder
    InterventionSSR149415
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Depression in the Elderly

    NCT00130455 · start 2006-04

    Registered record
    Registry ID
    NCT00130455
    Conditions
    Depression
    Interventions
    escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2006-04
    Completion
    2008-01
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    Interventionescitalopram
    PhasePhase 4
    Registry statusTerminated

  • PACEPro - Mood Management Pilot

    NCT00416221 · start 2006-04

    Registered record
    Registry ID
    NCT00416221
    Conditions
    Depression
    Interventions
    Lexapro, an antidepressant medicine; Physical Activity; Mood Management Skills; Personalized support from a Family Nurse Practitioner
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionLexapro, an antidepressant medicine; Physical Activity; Mood Management Skills; Personalized support from a Family Nurse Practitioner
    PhaseNot applicable
    Registry statusCompleted

  • Memory Functioning and Antidepressant Treatment

    NCT00296933 · start 2005-12

    Registered record
    Registry ID
    NCT00296933
    Conditions
    Depression; Major Depressive Disorder
    Interventions
    Escitalopram; Bupropion XL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Major Depressive Disorder
    InterventionEscitalopram; Bupropion XL
    PhasePhase 3
    Registry statusCompleted

  • Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

    NCT00135421 · start 2005-11

    Registered record
    Registry ID
    NCT00135421
    Conditions
    Major Depressive Disorder
    Interventions
    Pexacerfont; Escitalopram; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2005-11
    Completion
    2007-10
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionPexacerfont; Escitalopram; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Medications for the Treatment of Dysthymic Disorder and Double Depression

    NCT00234312 · start 2005-09

    Registered record
    Registry ID
    NCT00234312
    Conditions
    Depression; Dysthymia
    Interventions
    escitalopram and sertraline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-09
    Completion
    2006-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Dysthymia
    Interventionescitalopram and sertraline
    PhasePhase 4
    Registry statusCompleted